CRL
Charles River Laboratories
NYSE: CRL · HEALTHCARE · DIAGNOSTICS & RESEARCH
$168.46
-2.40% today
Updated 2026-06-05
Market cap
$9.03B
P/E ratio
—
P/S ratio
2.24x
EPS (TTM)
$-3.71
Dividend yield
—
52W range
$143 – $229
Volume
0.9M
Charles River Laboratories (CRL) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$168.46
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$161.90
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $3.5B | $4.0B | $4.1B | $4.0B | $4.0B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -4.59%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.